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Table
Multivariate analysis for overall survival after HCT
Variable Hazard ratio 95% CI P value
Race Ethnicity
White 1.0
Non-white/ Hispanic 1.72 1.03 to 2.87 0.04
Age
<50 1.0
 50 1.60 0.95 to 2.70 0.07
Disease
Lymphoma 1.0
Leukemia/ MDS 1.18 0.58 to 2.42 0.64
Others 1.36 0.42 to 4.41 0.6
Disease risk
Low 1.0
Intermediate 1.24 0.66 to 2.35 0.5
High 2.36 1.39 to 4.00 0.001
Donor
Related 1.0
Unrelated 1.45 0.94 to 2.22 0.08
Conditioning
Reduced intensity 1.0
Myeloablative 1.39 0.85 to 2.3 0.19
Karnofsky performance score
100 1.0
<100 2.92 1.82 to 4.69 < .001
HCT-CI score 1.08 0.97 to 1.19 0.13
CMV status
D-/R- 1.0
Others 1.5 0.85 to 2.64 0.16
Employment status
Employed 1.0
Unemployed 1.03 0.63 to 1.69 0.9
Retired 1.44 0.84 to 2.48 0.18
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S295Higher risk of mortality from HCT in the ethnic minorities
underscores the need for better understanding of the factors
responsible for differential outcomes and continued efforts
to eliminate disparities in access and outcomes of HCT.
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Outcome of Second Transplants in Pediatric Patients with
Hematological Malignancies After a Hematopoietic Stem
Cell Transplant (HSCT) From a Different Donor.
Assessment of Chimerism by Real -Time PCR to
Determine the Risk of Relapse
Sana Khan 1, Marie Olszewski 2, Morris Kletzel 3. 1 Lurie
Children's Hospital, Chicago, IL; 2 Lurie Children's Hospital,
Chicago; 3 Northwestern University Feinberg School of
Medicine, Chicago, IL
A retrospective analysis of 13 patients (9males, 4 females)
aged 1-16 (median, 9) years were transplanted at Lurie
Children's between 2002 to 2011 (AML n¼ 2, ALL n¼11).
Donor sources for the 1st HSCT were 8 match related sibling
(MRS) and 5 unrelated (2/5 cord blood) and for the 2nd HSCT
were 5 MRS and 8 unrelated. Two conditioning regimens; A:
fractionated TBI 1200cGy in 150cGy fractions from day -7 to
-4, Etoposide 1000 mg/m2 from day -3 and Cyclophospha-
mide 60 mg/Kg day -3 to day -1, 1st HSCT (n¼7) and 2nd HSCT
(n¼6), B: Fludarabine 30 mg/m2/day from day -10 to -6,
Busulfan (dose based on PK of the test dose to achieve an AUC
4000microM-min/day) day -5, -4 and ATG (rabbit ATG) 2mg/
kg from day -4 to -9, 1st HSCT (n¼3) and 2nd HSCT (n¼10).
GVHD prophylaxis was regimen speciﬁc for regimen A (CSA/
Tacro, short course MTX  ATG) and regimen B (CSA/Tacro,
MMF ECP). Chimerism was evaluated by real-time PCR
(Applied Biosystems 7500) using AlleleSEQR (Cellera),
weekly after the second week, full donor chimerism (FDC)
was deﬁned as >98%  1%. Median time from diagnosis to1st HSCT was 202 days. The median time from the 1st to the
2nd HSCT was 531 days. ANC > 500 /mL was achieved at
a median of 15 (10-39) days in the 1st, compared to 18.5 (10-
25) days after the 2nd (P ¼ .7). Un-sustained platelet count
>20.0/ mL was attained at amedian of 16.5 (1-54) days and 19
(0-54) days at 1st and 2nd (P ¼ .8), respectively. FDC was
achieved at a median of 34.5 (12-63) days in 13/13 after the
1st and a median of 44 (22-108) days in 10/13 after the 2nd.
The median follow-up after the 2nd HSCT was 1259 (35-
3508) days. The Kaplan- Meier estimates of survival at 3 and
5 years were 69.2% and 43.3%, respectively (median follow up
of 1735 days). Seven patients (1 with partial chimerism, 6
with FDC) are alive after the 2nd HSCT, free of disease with
a median follow up of 1562 (range 915-3508) days. Six
patients have expired, three of cGVHD complications in
remission (3 with FDC) and three patients expired from
progressive leukemia (2 with partial chimerism). Patients
who relapse after the 1st myeloablative HSCT can be
successfully treated with a 2nd HSCT from a different donor.
Patients who did not achieve a FDC after the 2nd transplant
were at a higher risk of relapse. One patient with partial
chimerism has remained in CR after developing graft failure
after the 2nd HSCT, but achieving FDC from the ﬁrst donor.
Patients who developed cGVHD after the 2nd transplant with
a FDC did not relapse but died of cGVHD complications in
remission. All but one of the surviving patients has cGVHD.
Chimerism analysis is the index for which the risk of relapse
is determined. Larger number of patients will be needed to
conﬁrm these preliminary observations.372
Outcome of Allogeneic Hematopoietic Stem Cell
Transplantation for Severe Aplastic Anemia Using
Fludarabine, Reduced-Dose Cyclophosphamide, and ATG
Sumiko Kohashi, Takehiko Mori, Jun Kato, Akiko Yamane,
Shinichiro Okamoto. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan
Background: Although allogeneic hematopoietic stem cell
transplantation (HSCT) has beenwidely performed for severe
aplastic anemia (SAA), the standard conditioning regimen
has yet to be established. Recently, the outcomes of a variety
of reduced-intensity conditioning regimens using ﬂudar-
abine have been reported.
Aims: We have retrospectively evaluated the safety and
efﬁcacy of allogeneic HSCT for SAA using ﬂudarabine,
reduced-dose cyclophosphamide, and ATG.
Patients & Methods: Six patients (median age 30 (range:
22-61)) with SAA who underwent allogeneic bone marrow
transplantation from an HLA-identical sibling (n¼3) or an
HLA-matched unrelated donor (n¼3) were evaluated.
Conditioning included ﬂudarabine (120 mg/m2), cyclop-
hosphamide (100 mg/kg), and ATG (Thymoglobulin;
3.75 mg/kg). In addition, 2 Gy of TBI (with ovarian shielding
for young female patients) was delivered for heavily trans-
fused patients or HSCT from an unrelated donor. For the
prophylaxis of graft-versus-host disease (GVHD), cyclo-
sporine A or tacrolimus with short-term methotrexate was
given.
Results: The transplant procedure was generally well-toler-
ated and there were no life-threatening complications. All
patients achieved neutrophil and platelet engraftment and
became transfusion independent. Full donor chimerism was
conﬁrmed on whole bone marrow cells at day 28 after
transplantation. Only one patient developed acute GVHD
(grade II) and none developed chronic GVHD. With a median
follow-up period of 15.9 months (range: 11.6-22.4 months),
